Exclusive: Houston startup rebrands to provide AI chat tool focused on women’s health

meet ema

A Houston founder is introducing you to ema — a GPT-based chat platform and your new best friend in women's health. Photo via Canva

Amanda Ducach set out to create a platform where mothers could connect with each other socially, but when she launched SocialMama just ahead of a global pandemic, she soon learned there was a bigger market need for access to information surrounding women's health — from fertility to menopause.

After pivoting her femtech platform to include women's health experts, she realized her technology wasn't able to completely support growing user base. The platform, which was called SocialMama, saw users engaging with experts in similar ways — and as Ducach looked into growing the platforms users, she realized that 24/7 access to experts was going to be hard to scale.

"We noticed that most of these conversations were repetitive," Ducach tells InnovationMap. "You had women asking an expert about tracking ovulation a hundred times a day. Having an OBGYN answer that question a hundred times a day was crazy and just not scalable."

Ducach says that about 16 months ago, her team took a step back to recreate the platform incorporating GPT technology. GPT stands for generative pre-trained transformer, and is a family of artificial intelligence language models most recently made popular but ChatGPT developed by OpenAI.

Now, after building out the platform, Ducach's company has rebranded to ema. The AI-based chat tool — named from the three letters in the middle of "female" — is meant to feel like texting "your childhood best friend who became an OBGYN physician," Ducach says. Not only can the chat provide crucial medical information, but it has a memory and can pick up conversations where they left off to be a constant resource to users.

The new platform, deemed ema, operates as an AI-based chat for women to engage with. Screenshot courtesy of ema

"Ema can answer everything from, 'how do I improve my baby's latch,' to 'how to I get a diabetic-friendly brownie recipe,' to 'give me an affirmation that's spoken like Snoop Dog because I'm feeling sad today,'" Ducach says.

Ducach first described the evolution of the company to AI-based communication last summer on the Houston Innovators Podcast. Now, the platform is gearing up for its launch next month and plans to raise seed funding this year to double her current team of 10 people to support the company's growth. Ducach, who was accepted into the Techstars Austin program in 2021, also says she's looking for more beta users in the meantime, and those interested should reach out to her or her team.

Ultimately, Ducach says the mission of ema is to democratize access to women's health care so that women feel supported and just a few taps away from important information.

"Barriers to care for women who face socioeconomic disparities is where you see the need for change," Ducach says. "For us, it's reducing those barriers of care. Ema is always in your pocket. You have access to her 24/7. The way that ema is really structured and her purpose is to catch red flags so that we can then help the female user get to positive health outcomes."

Amanda Ducach founded the company in 2019. Photo via Twitter

From Your Site Articles
One way to move the needle on developing femtech, according to this expert, is to make sure women have a seat at the table at venture firms funding the innovations. Photo via Getty Images

The growing femtech industry needs more attention — and funds, says this Houston expert

guest column

Femtech is a term that is generally given to medical products, software, and technologies that aim to enhance the health and wellbeing of women. But when people think of femtech, things like period tracker apps and pregnancy tests are usually the first things to come to mind. While those developments are important and used regularly, there are other diseases and chronic issues affecting women that need to be talked about as well.

The concept of femtech shouldn't replace "women's health" which considers broader issues, such as endometriosis and PCOS, as well as other conditions — such as heart disease — common to both men and women but clinically different in the latter. Femtech investors, manufacturers, and health advocates should focus on creating solutions for all issues and diseases that affect women, not just the most obvious.

However, more education and awareness is necessary to bring these issues to the forefront, as many people are not aware about how certain chronic issues and diseases affect women differently than they may affect men. For example, heart disease is the leading cause of death in women and men, but if you close your eyes and envision someone having a heart attack — do you see a man? Or a woman? Probably a man. And you're not alone. Because so much of our healthcare research has focused primarily on men, we are programmed to think of certain conditions affecting men predominantly when they are truly major health issues for both.

Similarly, when it comes to memory loss, women have a 1 in 5 chance of developing Alzheimer's disease compared to men being 1 in 11. Additionally, out of the more than 5 million people living with Alzheimer's in the U.S., 3.2 million are women. While there aren't as many Femtech-related products or solutions focused on these issues, there should be, especially in a rapidly growing industry.

According to the U.S. Clinical Laboratory Test Market, the femtech industry is expected to grow at a compound annual growth rate of more than 13 percent. Frost and Sullivan predicts the global Femtech market revenue will reach $1.1 billion by 2024, and BIS Research forecasts that by 2030 the sector will hit $3.04 billion. But even with great momentum, there is a knowledge gap that needs to be bridged. Overall, the industry has been underfunded and many opportunities have been overlooked, not necessarily because of gender. But, because investors in the industry are predominantly men, there is a lack of education and understanding of why these products are needed.

A solution would be for more women to become investors. Women have the personal experience and a better understanding of how these products will benefit them, which allows them to better understand the story told, increasing the chance the product will be funded and brought to market. To fund life-changing inventions for women, we need to have women involved, which means we need women to step into the investment community. Until more women get a seat at the investment table, women in femtech who are looking for investors need to be prepared to share real life stories and provide as much information as possible to have a better chance of securing funding.

The femtech industry is growing, and we will continue to see innovative devices and apps brought to market. With more education, a better understanding of other issues that affect women, and more female investors, the industry has the potential to take its growth to a new level.

------

Isabella Schmitt currently serves as the director of regulatory affairs at Proxima Clinical Research Inc.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.

Rice University lands $14M state grant to open Center for Space Technologies

on a mission

Rice University’s Space Institute soon will be home to the newly created Center for Space Technologies.

On Feb. 17, the Texas Space Commission approved a nearly $14.2 million grant for the Rice project. The Center for Space Technologies will target:

  • Research and development
  • Technology transfer and innovation
  • Statewide partnerships
  • Workforce development training
  • Space-focused education programs

The goal of the new center “is to fulfill an articulated need for research, workforce development, and industry collaboration,” said Kemah communications and marketing executive Gwen Griffin, chair of the commission.

State Rep. Greg Bonnen, a Friendswood Republican, authored the bill that set up the Texas Space Commission.

Since being authorized in 2023, the commission has funded 24 projects, with Rice and Houston-area companies accounting for nearly $75 million in grants to back space-related initiatives.

The grant to Rice brings the TSC's total investment to $150 million, fully committing the entire state appropriation from the Texas Legislature in 2023.

Other local companies that have received grants over the years include Aegis Aerospace, Axiom Space, Intuitive Machines, Starlab Space and Venus Aerospace.

The commission also awarded $7 million to Blue Origin earlier this month. See a list of the 24 awards here.

Waymo self-driving robotaxis have officially launched in Houston

Waymo has arrived

Waymo will begin dispatching its robotaxis in four more cities in Texas and Florida, expanding the territory covered by its fleet of self-driving cars to 10 major U.S. metropolitan markets.

The move into Dallas, Houston, San Antonio and Orlando, Florida, announced Tuesday, February 24, widens Waymo's early lead in autonomous driving while rival services from Tesla and the Amazon-owned Zoox are still testing their vehicles in only a few U.S. cities.

In contrast, Waymo's robotaxis already provide more than 400,000 weekly trips in the six metropolitan areas where they have been transporting passengers: Phoenix, the San Francisco Bay Area, Los Angeles, Miami, Atlanta, and Austin, Texas.

Waymo operates its ride-hailing service through its own app in all the U.S. cities except Atlanta and Austin, where its robotaxis can only be summoned through Uber's ride-hailing service.

The expansion into four more markets marks a significant step toward Waymo's goal to surpass 1 million weekly paid trips by the end of 2026. Without identifying where its robotaxis will be available next, Waymo is targeting a list of eight other cities that include Las Vegas, Washington, Detroit and Boston while signaling its first overseas availability is likely to be London.

To help pay for more robotaxis, Waymo recently raised $16 billion as part of the financial infusion that puts the value of the company at $126 billion. The valuation fueled speculation that Waymo may eventually be spun off from its corporate parent Alphabet, where it began as a secret project within Google in 2009.

Although Waymo is opening up in four more cities, its robotaxis initially will only be made available to a limited number of people with its ride-hailing app in Dallas, Houston, San Antonio and Orlando before the service will be available to all comers in those markets.

View All Listings